In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer-Reference-Cited by-同舟云学术

In Vitro and In Vivo Activity of Cabozantinib (XL184), an Inhibitor of RET, MET, and VEGFR2, in a Model of Medullary Thyroid Cancer

Published:2013-12 Issue:12 Volume:23 Page:1569-1577
ISSN:1050-7256
Container-title:Thyroid
language:en
Short-container-title:Thyroid

Author:

Bentzien Frauke¹,Zuzow Marcus¹,Heald Nathan¹,Gibson Anna¹,Shi Yongchang¹,Goon Leanne¹,Yu Peiwen¹,Engst Stefan¹,Zhang Wentao¹,Huang Donghui¹,Zhao Lora¹,Vysotskaia Valentina¹,Chu Felix¹,Bautista Rajana¹,Cancilla Belinda¹,Lamb Peter¹,Joly Alison H.¹,Yakes F. Michael¹

Affiliation:

1. Exelixis, Inc., South San Francisco, California.

Publisher

Mary Ann Liebert Inc

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism

Link

https://www.liebertpub.com/doi/pdf/10.1089/thy.2013.0137

Reference54 articles.

1. Cancer Statistics, 2009

2. A transplantable human medullary thyroid carcinoma as a model for RET tyrosine kinase-driven tumorigenesis

3. Medullary thyroid cancer: early detection and novel treatments